Objective: to investigate the effect of bedazinoline in treating patients with multidrug-resistant tuberculosis. Methods: from 2021 to 2021, aNTI-TB treatment regimen: 6 betadaquine MOXIFLOXACIN chlorfazimine cycloser...Objective: to investigate the effect of bedazinoline in treating patients with multidrug-resistant tuberculosis. Methods: from 2021 to 2021, aNTI-TB treatment regimen: 6 betadaquine MOXIFLOXACIN chlorfazimine cycloserine or linezolid 12 paracel Islands chlorfazimine cycloserine or linezolid, in which betadaquine depends on weight, which is less than 30kg/mg. d for patients, 200 mg once a day, 3 times a week after 2 weeks, 100 mg;Weight 30-50 kg/mg. d for patients, 400 mg once a day, three times a week after 2 weeks, 200 mg each time;Weight greater than 50 kg/mg. d for patients were given 400 mg once a day and 200 mg three times a week after 2 weeks. The effect of treatment and the serological inflammatory status and immune function level of patients before and after treatment were analyzed, and the adverse reactions were analyzed. Results: in 18 patients, 10 were effective, 6 effective, 2 ineffective, and the treatment effect was 88.89%. Patient serological inflammation index CRP was lower than before treatment, IFN-higher than before treatment, immune function level was higher than before treatment, P <0.05. After treatment, there was one arthralgia, one gastrointestinal response, and one leukopenia. All of the treated symptoms disappeared. Conclusion: the application effect of multidrug-resistant tuberculosis and the control of inflammation have no serious adverse effects.展开更多
文摘Objective: to investigate the effect of bedazinoline in treating patients with multidrug-resistant tuberculosis. Methods: from 2021 to 2021, aNTI-TB treatment regimen: 6 betadaquine MOXIFLOXACIN chlorfazimine cycloserine or linezolid 12 paracel Islands chlorfazimine cycloserine or linezolid, in which betadaquine depends on weight, which is less than 30kg/mg. d for patients, 200 mg once a day, 3 times a week after 2 weeks, 100 mg;Weight 30-50 kg/mg. d for patients, 400 mg once a day, three times a week after 2 weeks, 200 mg each time;Weight greater than 50 kg/mg. d for patients were given 400 mg once a day and 200 mg three times a week after 2 weeks. The effect of treatment and the serological inflammatory status and immune function level of patients before and after treatment were analyzed, and the adverse reactions were analyzed. Results: in 18 patients, 10 were effective, 6 effective, 2 ineffective, and the treatment effect was 88.89%. Patient serological inflammation index CRP was lower than before treatment, IFN-higher than before treatment, immune function level was higher than before treatment, P <0.05. After treatment, there was one arthralgia, one gastrointestinal response, and one leukopenia. All of the treated symptoms disappeared. Conclusion: the application effect of multidrug-resistant tuberculosis and the control of inflammation have no serious adverse effects.
